Reviva Operating Income from 2010 to 2024
| RVPH Stock | USD 1.15 0.01 0.88% |
Operating Income | First Reported 2018-09-30 | Previous Quarter -7.9 M | Current Value -8.1 M | Quarterly Volatility 4 M |
Check Reviva Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Reviva Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 156.3 K, Income Tax Expense of 25.1 K or Tax Provision of 10 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 6.36. Reviva financial statements analysis is a perfect complement when working with Reviva Pharmaceuticals Valuation or Volatility modules.
Reviva | Operating Income |
Latest Reviva Pharmaceuticals' Operating Income Growth Pattern
Below is the plot of the Operating Income of Reviva Pharmaceuticals Holdings over the last few years. Operating Income is the amount of profit realized from Reviva Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Reviva Pharmaceuticals Holdings is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Reviva Pharmaceuticals' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Reviva Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
Reviva Operating Income Regression Statistics
| Arithmetic Mean | (7,843,097) | |
| Coefficient Of Variation | (178.58) | |
| Mean Deviation | 10,676,109 | |
| Median | (376,860) | |
| Standard Deviation | 14,006,299 | |
| Sample Variance | 196.2T | |
| Range | 39.1M | |
| R-Value | (0.75) | |
| Mean Square Error | 91.8T | |
| R-Squared | 0.57 | |
| Significance | 0 | |
| Slope | (2,355,552) | |
| Total Sum of Squares | 2746.5T |
Reviva Operating Income History
About Reviva Pharmaceuticals Financial Statements
Investors use fundamental indicators, such as Reviva Pharmaceuticals' Operating Income, to determine how well the company is positioned to perform in the future. Although Reviva Pharmaceuticals' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Operating Income | -39.5 M | -37.5 M |
Currently Active Assets on Macroaxis
When determining whether Reviva Pharmaceuticals is a strong investment it is important to analyze Reviva Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Reviva Pharmaceuticals' future performance. For an informed investment choice regarding Reviva Stock, refer to the following important reports:Check out the analysis of Reviva Pharmaceuticals Correlation against competitors. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Reviva Pharmaceuticals. If investors know Reviva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Reviva Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.08) | Return On Assets (2.34) | Return On Equity (17.95) |
The market value of Reviva Pharmaceuticals is measured differently than its book value, which is the value of Reviva that is recorded on the company's balance sheet. Investors also form their own opinion of Reviva Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Reviva Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Reviva Pharmaceuticals' market value can be influenced by many factors that don't directly affect Reviva Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Reviva Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Reviva Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Reviva Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.